tirzépatide effets secondaires Médicaments anti-obésité: quels ? Tirzepatide 2026 : Mounjaro, -22,5%

We were unable to process your request

A large real-world cohort of 547,993 matched patients (Vidal/Akiska et al., JAAD International 2026) showed, at 12 months, an increased risk of both telogen effluvium (raised by around 76%) and androgenetic alopecia (raised by around 64%)

At Klinic, based in New York, we provide three FDA-approved weight loss treatments: Zepbound, Oral Wegovy, and Foundayo

It is not used for type 1 diabetes

Pre-restart assessment should include: Review of the reason for discontinuation and whether it has been adequately addressed Current weight and glycemic status (if diabetic) Assessment of gastrointestinal symptoms and any contraindications Medication reconciliation to identify potential drug interactions For patients taking insulin or sulfonylureas, consider dose reductions to prevent hypoglycemia For women of childbearing potential using oral contraceptives, recommend backup contraception for 4 weeks after restarting and after each dose increase Discussion of realistic expectations and commitment to continued treatment Patient counseling is essential